Exscientia

Laura Thompson, one of our Senior Scientists, presented yesterday at Discovery on Target on the automation of a cellular biosensor assay to allow for efficient hit compound screening.   Download the poster to learn how automating cellular assays can potentially reduce the cost, labour and timelines for drug discovery programmes: https://lnkd.in/eM8gqM49    #automation #drugdiscovery 

Otto Morris, Senior Biological Data Scientist, is presenting today at ELRIG UK Drug Discovery on DepExML, our explainable machine learning pipeline for identifying predictive biomarkers from dependency datasets. Download our poster to learn how DepExML generates actionable insights into complex cancer biology, providing translatable opportunities to develop novel, potential first-in-class drugs to address clinical unmet needs in precisely defined patient groups. https://lnkd.in/erpu77xx     #elrig #elrigdd24 #drugdiscovery #machinelearning 

Our collaborators from Professor Millán’s Lab at Sanford Burnham Prebys presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting today, showing for the first time that ENPP1 is a druggable target for late-onset hypophosphatasia (HPP), a rare and often severe disease. In in vivo studies using our AI-designed tool ENPP1 inhibitor compound, REV101, pyrophosphate (PPi) was significantly lowered to normal concentrations and improvements in mineralisation of bones were shown, which are key functional readouts for disease pathology. Together with Rallybio, we’re developing an ENPP1 inhibitor with improved properties compared with REV101 as a differentiated therapy to address unmet need in patients with HPP. We look forward to sharing more information with you soon. Download our ASBMR poster here: https://bit.ly/EXAI_ASBMR #rarediseases #AI #drugdiscovery #ASBMR2024

Mason Burlage, Cheminformatics Research Scientist, is presenting today on SALSA – our new approach to virtual chemical space exploration.     Download the poster to read how SALSA has the potential to accelerate drug discovery. It enables the efficient exploration of ultra-large chemical spaces, leading to the identification of novel and effective therapeutics: https://lnkd.in/eZAUM6ij     #EuroQSAR #AI #drugdiscovery 

Many thanks to Amazon Web Services (AWS), for highlighting our work in reimagining drug discovery, enabled by their cloud services! Read about our innovative Design-Make-Test-Learn cycles, integrating generative AI drug design and robotic lab automation and built on AWS, to help improve the efficiency and effectiveness of drug discovery. #DMTL #automation #AI #generativeAI 

If you’re attending the 24th EuroQSAR this week, make sure to catch Exscientia’s presentations.     Our CTO, John Overington, will be presenting a plenary lecture (PL12) on emerging AI approaches to drug discovery.    We’ll also have posters detailing our drug-induced liver injury models and scalable active learning over synthon space.    Review the programme here: https://lnkd.in/ebsh4UhP     #EuroQSAR #AI #drugdiscovery 

September is #BloodCancerAwarenessMonth – a time to highlight the impact of blood cancers and the urgent ongoing need for cutting-edge research.     At Exscientia, we’re harnessing our AI-driven platform to tackle some of the hardest-to-treat blood cancers including AML and CLL, with the aim to target the underlying drivers of disease.     Innovation is the key to delivering the next wave of treatments, including our LSD1 and MALT1 inhibitors, which will soon be entering clinical trials, and bringing hope to people affected by blood cancer.  #AI #DrugDiscovery

Konstantinos Papachristos, Senior Computational Drug Designer, is presenting today on how we’re using novel AI-designed bispecifics to tackle malaria – hitting two targets simultaneously to potentially prevent resistance emerging.    Download his poster to learn more about our malaria programme and about our bispecifics platform, which is applicable to any indication where single-target bioactivity data is available: https://bit.ly/EXS_Malaria #AI #DrugDiscovery #Malaria #NTGH24 RSC BMCS

Giovanni Bocci, Senior Discovery Data Scientist, is presenting on our drug-induced liver injury (DILI) models at the EUROTOX Congress today. Download his poster to learn about our range of models, which have been developed with more DILI-relevant features and endpoints. Using these models, we aim to improve early estimation of DILI in potential drug candidates and overall improve drug safety and attrition: https://lnkd.in/ex_uTMyE #druginduced #liverinjury #drugdevelopment #EUROTOX2024

We’re excited that Nicola Richmond Ph.D., will be joining the Exscientia team in September as Chief Scientist, AI. With a Ph.D. in mathematics, she brings over 20 years of experience operating at the intersection of drug discovery and technology. Nicola will be leading Exscientia’s work to develop AI solutions for the Company’s drug discovery efforts.  #AI #DrugDiscovery